top of page
NEWS / BLOG
Search
All Posts


BioMADE Invests $214M in Projects Advancing the Future Biomanufacturing Workforce.
With funding from the U.S. Department of War and the U.S. National Science Foundation, these projects will support the production of critically needed goods and materials, strengthen the domestic supply chain, and build a 21st century workforce. MINNEAPOLIS-ST. PAUL, MN/EMERYVILLE, CA, April 29, 2026 – Today, BioMADE announced 14 cutting-edge new projects that will support the growth and development of the U.S. bioindustrial manufacturing industry. These projects will support
Apr 293 min read


The Innovation Illusion: Why Biopharma Breakthroughs aren't Moving the Market
A new analysis, the Global Biopharma Index , by Cytiva Life Sciences examines global biopharma performance across six indexes. Based on survey responses from over 1200 industry executives in 2025, the index highlights the threat that critical workforce shortages in areas such as cell and gene therapy are having on scientific advancements across the globe. Download the report here .
Apr 191 min read


LSWC Leadership Engages at National Biotechnology Symposium
Several members of the Life Sciences Workforce Collaborative (LSWC) Board were in Washington, D.C. on March 25 to participate in the Biotech Across America State Symposium, hosted by the National Security Commission on Emerging Biotechnology.
Apr 191 min read


LSWC Takes the Stage at SynBioBeta 2026
The Life Sciences Workforce Collaborative (LSWC) will be represented on the global stage this May at SynBioBeta 2026 Synthetic Biology Summit, one of the premier gatherings at the intersection of biology, technology, and innovation. Maria Thacker Goethe will moderate a featured session, “Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy,” highlighting the critical role of workforce development and bioliteracy in maintaining U.S. leadership in biotechnolog
Apr 191 min read


VABio Welcomes $120M Investment in Training for Advanced Pharmaceutical Manufacturing
Gov. Glenn Youngkin signed on Oct. 31, 2025, a memorandum of understanding with AstraZeneca, Eli Lilly, Merck and state entities to establish a training center. Photo by Katherine Schulte/Virginia Business Following the announcement of a combined $120 million investment in workforce training by AstraZeneca, Eli Lilly & Co., and Merck & Co. late last year, Virginia’s biotech ecosystem is rapidly gaining momentum. With an additional $10 million provided by the state, these inve
Apr 191 min read
bottom of page

